Generate Biomedicines, Inc.
GENB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002100782
In the last 90 days, Generate Biomedicines, Inc. insiders filed 0 open-market purchases and 1 sale; 86 institutions reported holding it in 13F filings for Q2 2026, worth $1.69B in total; ARK Invest is the only superinvestor holding it.
Holders of 5% or more of GENB
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Generate Biomedicines, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 13G | 48.90%62.7M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Nally Michael | 13G | 5.20%6.92M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
2 Schedule 13D and 13G filings on Generate Biomedicines, Inc., newest first, including old-format filings without a stake.
No Schedule 13D or 13G filings on Generate Biomedicines, Inc. are on file.
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Generate Biomedicines, Inc. shares.
No Form 144 notices for Generate Biomedicines, Inc. are on file.